thioacetamide and Hemolysis

HESA-A, a marine compound, has been shown to exhibit antihepatic cancer, antitumor and anti-Parkinson effects. The hepatoprotective potential of HESA-A pretreatment at doses of 125 mg and 250 mg per day orally for a period of 40 days was evaluated against thioacetamide-induced liver damage in rabbits. Biochemical parameters such as serum glutamate oxaloacetate transaminase and lactate dehydrogenase in serum were estimated to assess liver function and lipid peroxidation products (malondialdehyde [MDA]) and the antierythrocyte lysis effect of plasma for measurement of antioxidant potential capacity. Data on the hepatic biochemical parameters revealed the hepatoprotective potential of HESA-A pretreatment against thioacetamide-induced hepatotoxicity in rabbits. There was an increase in total antioxidant and antierythrocyte lysis and a decrease in MDA in plasma after HESA-A treatment. These results strongly suggest that HESA-A has a protective action against preoperative damage to biomembranes.

Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Hemolysis; Lipid Peroxidation; Liver Function Tests; Male; Plant Preparations; Rabbits; Thioacetamide